Thiogenesis Therapeutics Inc.

(TSXV: TTI | OTCQX: TTIPF)

A clinical-stage biopharmaceutical company developing next-generation, sulfur-based therapeutics, classified as thiols, to address oxidative stress and inflammation in inherited and acquired mitochondrial diseases.

TTI-0102, a prodrug of cysteamine, enhances delivery, bioavailability, and tolerability, overcoming the limitations of past thiol-based drugs. Early clinical data indicates TTI-0102 is well tolerated at high doses. 

With an experienced leadership team in orphan drug development, the company follows a capital-efficient strategy:

• 505(b)(2) regulatory pathway in the U.S.
• Small, focused human efficacy trials
• Substantial addressable orphan markets with unmet need

An IND (U.S.) is planned for a Phase 3 clinical trial in Nephropathic Cystinosis in 2026. In addition, Phase 2 trials are ongoing in MELAS (Europe) and cleared for the Leigh syndrome spectrum (U.S.), with plans to file for an IMPD (Europe) in pediatric fatty liver disease.